Developer docs
API playgroundTry for free, no card

Search company profiles

Humanwell Pharmaceutical

Full company profile

uuid000j2h5

Namestring
Humanwell Pharmaceutical
Legal namestring
Humanwell Pharmaceutical US, Inc.
Websiteurl
humanwellus.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Humanwell Pharmaceutical US, Inc. is a Missouri-incorporated, privately-held pharmaceutical R&D company founded in September 2015 as an independent US subsidiary of Yichang Humanwell Pharmaceutical Co. LTD. Headquartered at 421 Sovereign Court, Ballwin, MO with 11-50 US employees (and access to a parent workforce of 4,000+ globally), the company develops novel therapeutics in pain management, CNS disorders, autoimmune disease, and oncology, building on its parent company's leadership position in anesthetic and analgesic medications. The technical stack combines AI/ML-augmented computational simulation (molecular dynamics, quantum mechanics, generative AI), an AI-assisted medicinal chemistry platform with computer-aided drug design and high-throughput screening, and a portfolio of proprietary drug delivery platforms including long-acting injectables, nanoparticle formulations, gastro-retentive tablets, geomatrix multi-layer matrix tablets, and bioavailability enhancement technologies. A pilot plant supports solid-dosage manufacturing for mini-tablets, capsules, oral suspensions, and nasal sprays.

The pipeline spans New Chemical Entities (NCE), 505(b)(2) candidates, and complex generics. The lead program is RFUS-250, a small-molecule analgesic binding all three opioid receptors (KOR, DOR, MOR), which received FDA IND clearance in February 2025 and is planned to enter Phase 1 in H2 2025 for acute, chronic, neuropathic pain, and pruritus indications. Execution milestones include a first ANDA filing (Q4 2020), first ANDA approval (Q3 2022), first NDA project approval (Q1 2023), and second ANDA approval (Q3 2023).

Revenue mechanics are not publicly disclosed and are described through three streams: (1) licensing/royalty income from the development and eventual commercialization of NCE, 505(b)(2), and complex generic products; (2) professional services and end-to-end development partnerships performed at the Missouri labs; and (3) licensing/royalty income from in-licensing branded and specialty assets into the parent company's Chinese hospital and critical care channels, where Yichang Humanwell is a market leader. Go-to-market is sales-led and BD-driven, with a dedicated partnership hotline (636-220-3636) and email channel (info@hmpharmaus.com), targeting hospital systems, IDNs, and procurement decision-makers in anesthesia, analgesia, ICU, and critical care settings; distribution is through pharmaceutical wholesalers and the parent's network spanning 20+ countries. Pricing is not publicly disclosed.

Short descriptiontext

Humanwell Pharmaceutical US, Inc. is a Missouri-based, privately-held pharmaceutical R&D subsidiary of Yichang Humanwell Pharmaceutical Co. LTD, developing NCE, 505(b)(2), and complex generic therapeutics in pain, CNS, autoimmune, and oncology using proprietary drug-delivery platforms and AI-assisted computational drug discovery, with lead asset RFUS-250 entering Phase 1 in 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBallwin, United States
HQ citystring
Ballwin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
novel therapeutics development, pharmaceutical R&D services, drug delivery platforms, anesthesia and analgesia, complex generic formulations
Industry4 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Research & Development
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Development
TypeLicensing Royalties
Description

Development and commercialization of novel therapeutics including NCE, 505(b)(2), and complex generic products in pain, CNS, autoimmune, and oncology. Revenue generated through eventual product sales and licensing.

humanwellus.com
2Development Partnerships
TypeProfessional Services
Description

End-to-end drug development services provided to partners through state-of-the-art labs and talented team in Missouri. Also includes in-licensing opportunities for branded and specialty assets in hospital and critical care channels.

humanwellus.com
3In-licensing Opportunities
TypeLicensing Royalties
Description

Yichang Humanwell serves as a leader in Chinese hospital medicine market, providing access to vast and growing market for partners with branded and specialty assets in hospital and critical care channels.

humanwellus.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Humanwell Pharmaceutical US is a pharmaceutical R&D company that discovers and develops novel therapeutics, including NCE, 505(b)(2), and complex generic products, across pain, CNS, autoimmune, and oncology indications. The company leverages proprietary drug delivery platforms (long-acting injectables, nanoparticles, gastro-retentive tablets, geomatrix tablets, bioavailability enhancement), AI-integrated computational simulation, and medicinal chemistry capabilities, alongside a solid-dosage pilot plant supporting formulation development. Lead candidate RFUS-250, a multi-opioid receptor analgesic, received FDA IND clearance in February 2025 for Phase 1 clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • RFUS-250 showed approximately 100 times more potent efficacy than morphine in rat formalin and incision pain models
+2 more records
Product overview1 text field

Humanwell Pharmaceutical US is a pharmaceutical R&D company developing novel therapeutics in pain, CNS, autoimmune, and oncology. The company operates a portfolio of drug delivery technology platforms (long-acting injectables, nanoparticles, gastro-retentive tablets, geomatrix tablets, bioavailability enhancement) supporting their pipeline of NCE, 505(b)(2), and complex generic products. Their lead candidate RFUS-250 is a novel analgesic currently in Phase 1 clinical trials. The company also maintains solid dosage manufacturing capabilities for mini-tablets, capsules, oral suspensions, and nasal sprays.

Product and service4 records
1RFUS-250
CategoryNovel small molecule analgesic (NCE)
Description

A novel small molecule analgesic with a unique pharmacodynamic profile that binds to all three opioid receptors (KOR, DOR, MOR); being developed for acute pain, chronic pain, neuropathic pain, and pruritus. The candidate demonstrated approximately 100x the potency of morphine in rat formalin and incision pain models with no respiratory depression, minimal constipation, low addiction potential, and no sedation at therapeutic doses, and entered Phase 1 clinical trials following FDA IND clearance.

2Pain, CNS, Autoimmune, and Oncology Development Pipeline
CategoryPharmaceutical development pipeline
Description

An emerging portfolio of NCE, 505(b)(2), and complex generic drug candidates targeting therapeutic areas including hospital and ambulatory care, ICU and critical care, CNS disorders, and oncology, designed to address unmet medical needs through Humanwell's proprietary drug delivery platforms.

3End-to-End Pharmaceutical Development Partnership Services
CategoryContract pharmaceutical R&D services
Description

End-to-end drug development services offered from Humanwell's Missouri labs, providing partners access to AI-integrated computational simulation, medicinal chemistry, formulation development, and solid-dosage manufacturing capabilities for co-development and contract R&D engagements.

4China Hospital Medicine In-Licensing Program
CategoryIn-licensing and market access program
Description

In-licensing program offering branded and specialty pharmaceutical asset owners access to the Chinese hospital medicine market through parent company Yichang Humanwell's established distribution and regulatory infrastructure across hospital and critical care channels.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Yichang Humanwell Pharmaceutical Co. LTD is the parent company and global market leader in anesthetic and pain medications. Humanwell US is an independent subsidiary. The parent company has over 4,000 employees and delivers products to over 20 countries. Yichang Humanwell provides strategic access to the Chinese hospital medicine market and in-licensing opportunities for branded and specialty assets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Computational drug discovery platform leveraging physics-based modeling and ML; comparable on the AI/ML-driven R&D layer that Humanwell has built into its medicinal chemistry pipeline.

TypeBroad incumbent
Description

Large specialty pharma with deep franchise in pain, CNS, and hospital injectable generics; multiple Humanwell leaders (Jun Yang, Subo Liao) previously worked there, indicating a comparable R&D and commercial scope.

TypeDirect peer
Description

Clinical-stage biotech developing selective KOR agonists for pruritus and pain; directly comparable to Humanwell's RFUS-250 (multi-opioid receptor modulator) in target indication and modality.

TypeBroad incumbent
Description

Global big-pharma with established pain/CNS franchises and proven AI-augmented discovery engines; VP Subo Liao is a former Pfizer Principal Scientist, and Pfizer is a relevant comparator for the AI plus medicinal chemistry approach.

TypeEmerging player
Description

AI-first biotech using ML-driven phenotypic screening for small-molecule discovery; comparable emerging AI drug discovery operator that could outpace Humanwell's internal computational platform over time.

TypeBroad incumbent
Description

Large biotech with a growing non-opioid acute pain portfolio (e.g., NaV1.8 inhibitors); competing for the same hospital-based pain market and investor mindshare that Humanwell targets with RFUS-250.

TypeDirect peer
Description

Specialty pharma focused on novel CNS-acting analgesics including opioid receptor modulators; directly competes with Humanwell's pipeline in differentiated opioid pharmacology for pain.

TypeBroad incumbent
Description

World's largest generic drugmaker with substantial pain/CNS specialty pipeline and complex-generic experience; directly comparable to Humanwell's 505(b)(2) and complex generic strategy.

TypeDirect peer
Description

Specialty pharma commercializing abuse-deterrent and pain products in the hospital and ambulatory channel; overlaps with Humanwell's target sales motion to hospital procurement and pain specialists.

TypeDirect peer
Description

Specialty pharma developing sublingual and novel-delivery analgesics for acute and post-operative pain; comparable delivery-platform-based approach and hospital-channel focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Humanwell Pharmaceutical

Pharmaceutical Research & Developmenthumanwellus.com

Humanwell Pharmaceutical US, Inc. is a Missouri-based, privately-held pharmaceutical R&D subsidiary of Yichang Humanwell Pharmaceutical Co. LTD, developing NCE, 505(b)(2), and complex generic therapeutics in pain, CNS, autoimmune, and oncology using proprietary drug-delivery platforms and AI-assisted computational drug discovery, with lead asset RFUS-250 entering Phase 1 in 2025.

What Humanwell Pharmaceutical does

Humanwell Pharmaceutical US, Inc. is a Missouri-incorporated, privately-held pharmaceutical R&D company founded in September 2015 as an independent US subsidiary of Yichang Humanwell Pharmaceutical Co. LTD. Headquartered at 421 Sovereign Court, Ballwin, MO with 11-50 US employees (and access to a parent workforce of 4,000+ globally), the company develops novel therapeutics in pain management, CNS disorders, autoimmune disease, and oncology, building on its parent company's leadership position in anesthetic and analgesic medications. The technical stack combines AI/ML-augmented computational simulation (molecular dynamics, quantum mechanics, generative AI), an AI-assisted medicinal chemistry platform with computer-aided drug design and high-throughput screening, and a portfolio of proprietary drug delivery platforms including long-acting injectables, nanoparticle formulations, gastro-retentive tablets, geomatrix multi-layer matrix tablets, and bioavailability enhancement technologies. A pilot plant supports solid-dosage manufacturing for mini-tablets, capsules, oral suspensions, and nasal sprays.

The pipeline spans New Chemical Entities (NCE), 505(b)(2) candidates, and complex generics. The lead program is RFUS-250, a small-molecule analgesic binding all three opioid receptors (KOR, DOR, MOR), which received FDA IND clearance in February 2025 and is planned to enter Phase 1 in H2 2025 for acute, chronic, neuropathic pain, and pruritus indications. Execution milestones include a first ANDA filing (Q4 2020), first ANDA approval (Q3 2022), first NDA project approval (Q1 2023), and second ANDA approval (Q3 2023).

Revenue mechanics are not publicly disclosed and are described through three streams: (1) licensing/royalty income from the development and eventual commercialization of NCE, 505(b)(2), and complex generic products; (2) professional services and end-to-end development partnerships performed at the Missouri labs; and (3) licensing/royalty income from in-licensing branded and specialty assets into the parent company's Chinese hospital and critical care channels, where Yichang Humanwell is a market leader. Go-to-market is sales-led and BD-driven, with a dedicated partnership hotline (636-220-3636) and email channel (info@hmpharmaus.com), targeting hospital systems, IDNs, and procurement decision-makers in anesthesia, analgesia, ICU, and critical care settings; distribution is through pharmaceutical wholesalers and the parent's network spanning 20+ countries. Pricing is not publicly disclosed.

Humanwell Pharmaceutical firmographics

Firmographics
Name
Humanwell Pharmaceutical
Legal name
Humanwell Pharmaceutical US, Inc.
Website
https://humanwellus.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Humanwell Pharmaceutical US, Inc. is a Missouri-based, privately-held pharmaceutical R&D subsidiary of Yichang Humanwell Pharmaceutical Co. LTD, developing NCE, 505(b)(2), and complex generic therapeutics in pain, CNS, autoimmune, and oncology using proprietary drug-delivery platforms and AI-assisted computational drug discovery, with lead asset RFUS-250 entering Phase 1 in 2025.
Ownership category
akta.pro rank

Humanwell Pharmaceutical industry classification

Industry
Product category
Pharmaceutical Research & Development
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals

Keywords

  • Novel therapeutics development
  • Pharmaceutical R&D services
  • Drug delivery platforms
  • Anesthesia and analgesia
  • Complex generic formulations

Where Humanwell Pharmaceutical is headquartered

Location

Headquarters

HQ city
Ballwin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Humanwell Pharmaceutical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Development: Development and commercialization of novel therapeutics including NCE, 505(b)(2), and complex generic products in pain, CNS, autoimmune, and oncology. Revenue generated through eventual product sales and licensing.
  2. Development Partnerships: End-to-end drug development services provided to partners through state-of-the-art labs and talented team in Missouri. Also includes in-licensing opportunities for branded and specialty assets in hospital and critical care channels.
  3. In-licensing Opportunities: Yichang Humanwell serves as a leader in Chinese hospital medicine market, providing access to vast and growing market for partners with branded and specialty assets in hospital and critical care channels.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Humanwell Pharmaceutical product offering

Product offering

Core offering

Humanwell Pharmaceutical US is a pharmaceutical R&D company that discovers and develops novel therapeutics, including NCE, 505(b)(2), and complex generic products, across pain, CNS, autoimmune, and oncology indications. The company leverages proprietary drug delivery platforms (long-acting injectables, nanoparticles, gastro-retentive tablets, geomatrix tablets, bioavailability enhancement), AI-integrated computational simulation, and medicinal chemistry capabilities, alongside a solid-dosage pilot plant supporting formulation development. Lead candidate RFUS-250, a multi-opioid receptor analgesic, received FDA IND clearance in February 2025 for Phase 1 clinical trials.

Product overview

Humanwell Pharmaceutical US is a pharmaceutical R&D company developing novel therapeutics in pain, CNS, autoimmune, and oncology. The company operates a portfolio of drug delivery technology platforms (long-acting injectables, nanoparticles, gastro-retentive tablets, geomatrix tablets, bioavailability enhancement) supporting their pipeline of NCE, 505(b)(2), and complex generic products. Their lead candidate RFUS-250 is a novel analgesic currently in Phase 1 clinical trials. The company also maintains solid dosage manufacturing capabilities for mini-tablets, capsules, oral suspensions, and nasal sprays.

Differentiator

Problem solved

Functional benefit

Products and services

  • RFUS-250 A novel small molecule analgesic with a unique pharmacodynamic profile that binds to all three opioid receptors (KOR, DOR, MOR); being developed for acute pain, chronic pain, neuropathic pain, and pruritus. The candidate demonstrated approximately 100x the potency of morphine in rat formalin and incision pain models with no respiratory depression, minimal constipation, low addiction potential, and no sedation at therapeutic doses, and entered Phase 1 clinical trials following FDA IND clearance.
  • Pain, CNS, Autoimmune, and Oncology Development Pipeline An emerging portfolio of NCE, 505(b)(2), and complex generic drug candidates targeting therapeutic areas including hospital and ambulatory care, ICU and critical care, CNS disorders, and oncology, designed to address unmet medical needs through Humanwell's proprietary drug delivery platforms.
  • End-to-End Pharmaceutical Development Partnership Services End-to-end drug development services offered from Humanwell's Missouri labs, providing partners access to AI-integrated computational simulation, medicinal chemistry, formulation development, and solid-dosage manufacturing capabilities for co-development and contract R&D engagements.
  • China Hospital Medicine In-Licensing Program In-licensing program offering branded and specialty pharmaceutical asset owners access to the Chinese hospital medicine market through parent company Yichang Humanwell's established distribution and regulatory infrastructure across hospital and critical care channels.

Quantifiable outcome

  • RFUS-250 showed approximately 100 times more potent efficacy than morphine in rat formalin and incision pain models
  • +2 more outcomes

Companies that use Humanwell Pharmaceutical

Customer profile

Segments5 records

Ideal customer profiles2 records

Humanwell Pharmaceutical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature8 records

Humanwell Pharmaceutical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Yichang Humanwell Pharmaceutical Co. LTDcoreStrategic or Co-development PartnerYichang Humanwell Pharmaceutical Co. LTD is the parent company and global market leader in anesthetic and pain medications. Humanwell US is an independent subsidiary. The parent company has over 4,000 employees and delivers products to over 20 countries. Yichang Humanwell provides strategic access to the Chinese hospital medicine market and in-licensing opportunities for branded and specialty assets.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Humanwell Pharmaceutical competitors and assessment

Company assessment

Others

  • Schrödinger, Inc. Computational drug discovery platform leveraging physics-based modeling and ML; comparable on the AI/ML-driven R&D layer that Humanwell has built into its medicinal chemistry pipeline.

Broad incumbents

  • Mallinckrodt Pharmaceuticals: Large specialty pharma with deep franchise in pain, CNS, and hospital injectable generics; multiple Humanwell leaders (Jun Yang, Subo Liao) previously worked there, indicating a comparable R&D and commercial scope.
  • Pfizer: Global big-pharma with established pain/CNS franchises and proven AI-augmented discovery engines; VP Subo Liao is a former Pfizer Principal Scientist, and Pfizer is a relevant comparator for the AI plus medicinal chemistry approach.
  • Vertex Pharmaceuticals: Large biotech with a growing non-opioid acute pain portfolio (e.g., NaV1.8 inhibitors); competing for the same hospital-based pain market and investor mindshare that Humanwell targets with RFUS-250.
  • Teva Pharmaceutical Industries: World's largest generic drugmaker with substantial pain/CNS specialty pipeline and complex-generic experience; directly comparable to Humanwell's 505(b)(2) and complex generic strategy.

Direct peers

  • Cara Therapeutics: Clinical-stage biotech developing selective KOR agonists for pruritus and pain; directly comparable to Humanwell's RFUS-250 (multi-opioid receptor modulator) in target indication and modality.
  • Trevena Inc: Specialty pharma focused on novel CNS-acting analgesics including opioid receptor modulators; directly competes with Humanwell's pipeline in differentiated opioid pharmacology for pain.
  • Collegium Pharmaceutical: Specialty pharma commercializing abuse-deterrent and pain products in the hospital and ambulatory channel; overlaps with Humanwell's target sales motion to hospital procurement and pain specialists.
  • AcelRx Pharmaceuticals: Specialty pharma developing sublingual and novel-delivery analgesics for acute and post-operative pain; comparable delivery-platform-based approach and hospital-channel focus.

Emerging players

  • Recursion Pharmaceuticals: AI-first biotech using ML-driven phenotypic screening for small-molecule discovery; comparable emerging AI drug discovery operator that could outpace Humanwell's internal computational platform over time.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Humanwell Pharmaceutical social profiles

Digital presence

Humanwell Pharmaceutical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Humanwell Pharmaceutical leadership team

Management profile

Number of profiles

Profiles3 records

Humanwell Pharmaceutical funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Humanwell Pharmaceutical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Humanwell Pharmaceutical

What does Humanwell Pharmaceutical do?

Humanwell Pharmaceutical US is a pharmaceutical R&D company that discovers and develops novel therapeutics, including NCE, 505(b)(2), and complex generic products, across pain, CNS, autoimmune, and oncology indications. The company leverages proprietary drug delivery platforms (long-acting injectables, nanoparticles, gastro-retentive tablets, geomatrix tablets, bioavailability enhancement), AI-integrated computational simulation, and medicinal chemistry capabilities, alongside a solid-dosage pilot plant supporting formulation development. Lead candidate RFUS-250, a multi-opioid receptor analgesic, received FDA IND clearance in February 2025 for Phase 1 clinical trials.

Is Humanwell Pharmaceutical a public or private company?

Humanwell Pharmaceutical is a private company. It is classified as corporate owned and is currently operating.

When was Humanwell Pharmaceutical founded?

Humanwell Pharmaceutical was founded in 2015. It employs 11 to 50 people.

Where is Humanwell Pharmaceutical based?

Humanwell Pharmaceutical is headquartered in Ballwin, United States, in the North America region.

How does Humanwell Pharmaceutical make money?

Three revenue lines are on record. Pharmaceutical Product Development is the primary driver. The others are development Partnerships and in-licensing Opportunities.

Who are Humanwell Pharmaceutical's main competitors?

Schrödinger, Inc. is listed as an others. Broad incumbents are Mallinckrodt Pharmaceuticals, Pfizer, Vertex Pharmaceuticals and Teva Pharmaceutical Industries. Direct peers are Cara Therapeutics, Trevena Inc, Collegium Pharmaceutical and AcelRx Pharmaceuticals. Recursion Pharmaceuticals is listed as an emerging player.

Does Humanwell Pharmaceutical have an API?

No public API is recorded for Humanwell Pharmaceutical.

What industry is Humanwell Pharmaceutical in?

Humanwell Pharmaceutical's product category is Pharmaceutical Research & Development. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales